Safety of Drugs during Pregnancy and Breastfeeding in Cystic Fibrosis Patients

Respiration. 2016;91(4):333-48. doi: 10.1159/000444088. Epub 2016 Mar 5.

Abstract

Health management of cystic fibrosis (CF) patients should be maximized during pregnancy and breastfeeding because of its significant impact on the maternal and newborn outcomes. Thus, numerous drugs will have to be continued during pregnancy and lactation. Most of the drugs representing CF treatment lines cross the placenta or are excreted into human milk. Research addressing the risks and benefits of drugs used in CF patients during pregnancy and lactation is often incomplete or challenged by limited methodology, which often leads to conflicting or inconclusive results. Yet, potential treatment benefits for CF pregnant patients most often outbalance potential risks for the unborn child.

Publication types

  • Review

MeSH terms

  • Breast Feeding*
  • Cystic Fibrosis / drug therapy*
  • Drug-Related Side Effects and Adverse Reactions*
  • Female
  • Fetus / drug effects
  • Humans
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Teratogens

Substances

  • Teratogens